Liberty One Investment Management LLC Has $395,000 Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Liberty One Investment Management LLC lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 15.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,629 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Liberty One Investment Management LLC’s holdings in Madrigal Pharmaceuticals were worth $395,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Bradley & Co. Private Wealth Management LLC increased its holdings in Madrigal Pharmaceuticals by 307.4% during the 1st quarter. Bradley & Co. Private Wealth Management LLC now owns 110 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 83 shares in the last quarter. Garda Capital Partners LP bought a new position in Madrigal Pharmaceuticals during the 1st quarter worth about $34,000. Russell Investments Group Ltd. bought a new position in Madrigal Pharmaceuticals during the 1st quarter worth about $55,000. Nisa Investment Advisors LLC increased its holdings in Madrigal Pharmaceuticals by 145.8% during the 1st quarter. Nisa Investment Advisors LLC now owns 236 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 140 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Madrigal Pharmaceuticals by 41.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 246 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 72 shares in the last quarter. Institutional investors own 79.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MDGL. StockNews.com assumed coverage on Madrigal Pharmaceuticals in a report on Thursday, August 17th. They set a “sell” rating for the company. Canaccord Genuity Group restated a “buy” rating and issued a $336.00 price objective on shares of Madrigal Pharmaceuticals in a report on Tuesday, July 18th. Oppenheimer decreased their price objective on Madrigal Pharmaceuticals from $350.00 to $285.00 and set an “outperform” rating for the company in a report on Wednesday, August 9th. Finally, B. Riley restated a “neutral” rating and issued a $224.00 price objective on shares of Madrigal Pharmaceuticals in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $309.18.

Madrigal Pharmaceuticals Trading Up 2.9 %

Madrigal Pharmaceuticals stock opened at $196.58 on Monday. Madrigal Pharmaceuticals, Inc. has a 52 week low of $57.21 and a 52 week high of $322.67. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.02 and a current ratio of 3.02. The stock has a market capitalization of $3.63 billion, a P/E ratio of -10.54 and a beta of -0.72. The stock has a 50-day simple moving average of $196.18 and a 200 day simple moving average of $241.11.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($4.69) EPS for the quarter, missing analysts’ consensus estimates of ($4.59) by ($0.10). Analysts expect that Madrigal Pharmaceuticals, Inc. will post -18.89 earnings per share for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH.